Elicio Therapeutics (ELTX) to Release Earnings on Tuesday

Elicio Therapeutics (NASDAQ:ELTX) is expected to announce its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.49) per share for the quarter. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:00 PM ET.

Elicio Therapeutics (NASDAQ:ELTX) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.02).

Elicio Therapeutics Stock Down 1.1%

Shares of NASDAQ ELTX traded down $0.12 during midday trading on Tuesday, hitting $10.66. 48,013 shares of the stock traded hands, compared to its average volume of 129,204. The company has a market cap of $199.25 million, a PE ratio of -4.07 and a beta of 1.12. Elicio Therapeutics has a one year low of $4.85 and a one year high of $14.93. The business has a 50 day moving average price of $11.28 and a two-hundred day moving average price of $9.51. The company has a debt-to-equity ratio of 5.75, a quick ratio of 2.38 and a current ratio of 2.38.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on ELTX shares. LADENBURG THALM/SH SH started coverage on Elicio Therapeutics in a report on Wednesday, April 15th. They set a “buy” rating and a $20.00 price objective for the company. Wall Street Zen upgraded Elicio Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 7th. HC Wainwright upped their price target on Elicio Therapeutics from $13.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Rodman & Renshaw upgraded Elicio Therapeutics to a “strong-buy” rating in a report on Tuesday, March 10th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Elicio Therapeutics in a report on Friday, April 24th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Elicio Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Institutional Investors Weigh In On Elicio Therapeutics

Institutional investors have recently bought and sold shares of the stock. CIBC Bancorp USA Inc. bought a new stake in Elicio Therapeutics during the third quarter worth $350,000. Cresset Asset Management LLC bought a new stake in Elicio Therapeutics during the third quarter worth $295,000. Millennium Management LLC bought a new stake in Elicio Therapeutics during the third quarter worth $250,000. Royal Bank of Canada bought a new stake in Elicio Therapeutics during the first quarter worth $225,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in Elicio Therapeutics during the fourth quarter worth $187,000. Institutional investors own 35.03% of the company’s stock.

Elicio Therapeutics Company Profile

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.